The biotechnology company BioNTech has made significant progress in developing an mRNA vaccine against skin cancer. According to the Mainz-based company, the drug candidate BNT111 shows positive results in a clinical study. The study reached its primary endpoint for investigating efficacy and showed a statistically significant improvement in the overall response rate in patients treated with BNT111 in combination with Cemiplimab, compared to historical controls.

This specifically means that more patients showed an improvement in their condition after being treated with the BioNTech drug candidate. "These Phase 2 results represent an important step towards our vision of personalized cancer medicine," stated Prof. Dr. Özlem Türeci, co-founder and Chief Medical Officer of BioNTech. She views mRNA as a key component of future cancer treatment paradigms, particularly for patients with anti-PD-(L)1-refractory or -resistant melanoma.

After the announcement of the study results, the BioNTech stock initially gained on the NYSE, but later gave up its gains and closed 0.62 percent lower at 86.20 USD.

BioNTech gained great notoriety with its mRNA vaccine during the COVID-19 pandemic and achieved enormous revenues and profits. However, the company recently recorded losses due to declining revenues from the vaccine. Therefore, investors react particularly positively to success reports about other product candidates from the company.